Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications

NCT04475588 is registered in ClinicalTrials.gov with Biocon Limited as lead sponsor.

NCT NCT04475588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04475588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications
Lead sponsor
Biocon Limited
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2020
Completion date
July 7, 2020
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid19, cytokine release syndrome